Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Overview | 9 | 1 |
| Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Comparative Analysis | 10 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics under Development by Companies | 11 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Products Glance | 13 | 3 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Products under Development by Companies | 16 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Products under Investigation by Universities/Institutes | 17 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Companies Involved in Therapeutics Development | 18 | 10 |
| AngioChem Inc. | 18 | 1 |
| ArmaGen Inc. | 19 | 1 |
| Athersys, Inc. | 20 | 1 |
| Bioasis Technologies Inc. | 21 | 1 |
| Eloxx Pharmaceuticals, Ltd. | 22 | 1 |
| Inventiva | 23 | 1 |
| OPKO Health, Inc. | 24 | 1 |
| PTC Therapeutics, Inc. | 25 | 1 |
| RegenxBio Inc. | 26 | 1 |
| Sangamo BioSciences, Inc. | 27 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Assessment | 28 | 9 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 36 |
| AGT-181 Drug Profile | 37 | 2 |
| ataluren Drug Profile | 39 | 8 |
| Cell Therapy for Mucopolysaccharidosis I Drug Profile | 47 | 2 |
| Cell Therapy to Activate Iduronidase for Hurler Syndrome Drug Profile | 49 | 1 |
| odiparcil Drug Profile | 50 | 1 |
| Oligonucleotide for Mucopolysaccharidosis I Drug Profile | 51 | 1 |
| pentosan polysulfate sodium Drug Profile | 52 | 1 |
| PF-05285401 Drug Profile | 53 | 11 |
| Recombinant Alpha-L-Iduronidase Replacement for Hurler Syndrome Drug Profile | 64 | 1 |
| Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile | 65 | 1 |
| Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile | 66 | 1 |
| RGX-111 Drug Profile | 67 | 2 |
| SB-318 Drug Profile | 69 | 2 |
| Small Molecules for Hurler Syndrome Drug Profile | 71 | 1 |
| Stem Cell Therapy for Type1 Mucopolysaccharidosis Drug Profile | 72 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Dormant Projects | 73 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Discontinued Products | 74 | 1 |
| Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Product Development Milestones | 75 | 11 |
| Featured News &Press Releases | 75 | 1 |
| May 09, 2016: Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting of the American Society of Gene and Cell Therapy | 75 | 2 |
| Mar 31, 2016: ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome | 77 | 1 |
| Feb 08, 2016: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I | 78 | 1 |
| Dec 30, 2015: FDA Grants Rare Pediatric Disease Designation to REGENXBIO RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I) | 79 | 1 |
| Nov 05, 2015: ArmaGen Receives Rare Pediatric Disease Designation from FDA for AGT-181 for the Potential Treatment of Hurler Syndrome | 79 | 1 |
| Oct 01, 2015: FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I | 80 | 1 |
| Sep 02, 2015: ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome | 80 | 1 |
| Apr 08, 2015: ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome | 81 | 1 |
| Dec 19, 2014: Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I | 81 | 1 |
| Feb 05, 2014: Mouse Study Shows Gene Therapy May Be Possible Cure for Hurler Syndrome | 82 | 1 |
| Jul 10, 2012: Athersys Receives Orphan Drug Designation For MultiStem In Hurler s Syndrome | 83 | 1 |
| Apr 20, 2012: Athersys Announces Publication Of Results Of Preclinical Study Of MultiStem In Cell Transplant | 84 | 2 |
| Appendix | 86 | 2 |
| Methodology | 86 | 1 |
| Coverage | 86 | 1 |
| Secondary Research | 86 | 1 |
| Primary Research | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 87 | 1 |